title: Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c.
abstract: Current treatments for breast cancer, a common malignancy in human females, are less than satisfactory because of high rates of metastasis. Glabridin (GLA), which acts through the FAK/ROS signaling pathway, has been used as an antioxidant and anti-metastatic agent. However, little is known regarding the effect of microRNA (miRNA) on GLA's anti-metastatic activity. The miRNA-200 family, which is frequently expressed at low levels in triple negative breast cancers, inhibits metastasis by blocking the epithelial-mesenchymal transition. Here, we found that GLA attenuated the migratory and invasive capacity of breast cancer cells by activating miR-200c. GLA induced the mesenchymal-epithelial transition in vitro and in vivo, as determined by increased expression of the epithelial marker, E-cadherin, and decreased expression of the mesenchymal marker, vimentin. Overexpression of miR-200c enhanced the expression of E-cadherin and decreased the expression of vimentin. Furthermore, in MDA-MB-231 and BT-549 breast cancer cells exposed to GLA, knockdown of miR-200c blocked the GLA-induced mesenchymal-epithelial transition and alleviated the GLA-induced inhibition of migration and invasion. Thus, elevation of miR-200c by GLA has considerable therapeutic potential for anti-metastatic therapy for breast cancer patients.
authors.affiliation: Key Laboratory of Modern Toxicology, Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Nanjing Medical University, Nanjing, China.
authors.forename: Xianqing
authors.initials: X
authors.lastname: Ye
authors.forename: Fei
authors.initials: F
authors.lastname: Jiang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
authors.forename: Juan
authors.initials: J
authors.lastname: Mu
authors.forename: Lu
authors.initials: L
authors.lastname: Si
authors.forename: Xingxing
authors.initials: X
authors.lastname: Wang
authors.forename: Shilong
authors.initials: S
authors.lastname: Ning
authors.forename: Zhong
authors.initials: Z
authors.lastname: Li
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D035683:MicroRNAs / Q000235:genetics*; D010636:Phenols / Q000494:pharmacology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015820:Cadherins; D007529:Isoflavones; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D010636:Phenols; C107601:glabridin
keywords: Breast cancer; epithelial-mesenchymal transition; glabridin; metastasis; microRNA-200c
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):5-8
references.pmid: 20005451
references.citation: PLoS One. 2012;7(4):e35957
references.pmid: 22558281
references.citation: Cancer Res. 2000 Oct 15;60(20):5704-9
references.pmid: 11059763
references.citation: J Cell Sci. 2011 Apr 1;124(Pt 7):999-1006
references.pmid: 21402873
references.citation: Oncogene. 2014 Mar 27;33(13):1680-9
references.pmid: 23584475
references.citation: Invest Clin. 2013 Jun;54(2):186-205
references.pmid: 23947008
references.citation: Mol Cell. 2008 Jan 18;29(1):9-22
references.pmid: 18206965
references.citation: J Mammary Gland Biol Neoplasia. 2011 Sep;16(3):205-19
references.pmid: 21822945
references.citation: Int Immunopharmacol. 2010 Oct;10(10):1185-93
references.pmid: 20633530
references.citation: J Biol Chem. 2011 Jul 22;286(29):25992-6002
references.pmid: 21596753
references.citation: J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34
references.pmid: 20490631
references.citation: Breast Cancer Res. 2011 Jun 10;13(3):110
references.pmid: 21682933
references.citation: J Am Coll Nutr. 2007 Jun;26(3):209-18
references.pmid: 17634165
references.citation: Int J Cancer. 2010 Mar 15;126(6):1283-90
references.pmid: 19877123
references.citation: Exp Eye Res. 2013 Oct;115:189-98
references.pmid: 23872359
references.citation: Biochem J. 2008 Apr 1;411(1):151-60
references.pmid: 18215142
references.citation: Carcinogenesis. 2013 Mar;34(3):713-22
references.pmid: 23250910
references.citation: Cell Death Dis. 2013 Oct 24;4:e884
references.pmid: 24157878
references.citation: J Intern Med. 2013 Aug;274(2):113-26
references.pmid: 23844915
references.citation: Nat Cell Biol. 2011 Mar;13(3):317-23
references.pmid: 21336307
references.citation: PLoS One. 2012;7(10):e47709
references.pmid: 23112837
references.citation: Afr J Tradit Complement Altern Med. 2009 Oct 15;7(1):17-23
references.pmid: 21304608
references.citation: Cancer Chemother Pharmacol. 2008 Oct;62(5):867-73
references.pmid: 18204840
references.citation: Life Sci. 2008 Jan 2;82(1-2):68-78
references.pmid: 18048062
references.citation: Acta Oncol. 2010 Jun;49(5):624-31
references.pmid: 20429724
references.citation: Toxicol Ind Health. 2009 May-Jun;25(4-5):321-4
references.pmid: 19651803
references.citation: Methods Mol Biol. 2009;568:7-19
references.pmid: 19582418
references.citation: Integr Cancer Ther. 2011 Dec;10(4):341-9
references.pmid: 21059620
references.citation: Nat Cell Biol. 2008 Feb;10(2):202-10
references.pmid: 18193036
references.citation: Nat Cell Biol. 2008 May;10(5):593-601
references.pmid: 18376396
references.citation: Mol Nutr Food Res. 2011 Feb;55(2):318-27
references.pmid: 20626003
references.citation: Cancer Res. 2011 Apr 15;71(8):3087-97
references.pmid: 21363915
references.citation: J Mol Med (Berl). 2014 Jan;92(1):53-64
references.pmid: 24005829
references.citation: Food Chem Toxicol. 2013 Jan;51:439-45
references.pmid: 22967722
references.citation: Gut. 2013 Sep;62(9):1315-26
references.pmid: 22735571
references.citation: Mol Cancer Ther. 2012 Oct;11(10):2193-201
references.pmid: 22821148
references.citation: Sci Signal. 2009 Oct 13;2(92):ra62
references.pmid: 19825827